Sign In
Buy SAN
$14.10
-0.0100 (-0.0709%)
At Close: Jul 31, 2026
Press Release: EUROAPI listing on Euronext Paris expected on May 6, 2022
05:30am, Friday, 01'st Apr 2022 GlobeNewswire Inc.
Communiqué de presse : Cotation d’EUROAPI sur Euronext Paris prévue le 6 mai 2022
05:30am, Friday, 01'st Apr 2022 GlobeNewswire Inc.
Press Release: Sanofi successfully priced an inaugural sustainability-linked bond indexed on access to medicines
05:00am, Thursday, 31'st Mar 2022 GlobeNewswire Inc.
Communiqué de presse : Sanofi lance avec succès une émission obligataire indexée sur l’accès aux médicaments
05:00am, Thursday, 31'st Mar 2022 GlobeNewswire Inc.
Communiqué de presse : Mise en ligne du document «Q1 2022 Memorandum for modelling purposes»
05:30am, Wednesday, 30'th Mar 2022 GlobeNewswire Inc.
Press Release: Availability of the Q1 2022 Memorandum for modelling purposes
05:30am, Wednesday, 30'th Mar 2022 GlobeNewswire Inc.
Press Release: Sanofi and IGM Biosciences Announce Collaboration Agreement for Oncology, Immunology and Inflammation Targets
05:00am, Tuesday, 29'th Mar 2022 GlobeNewswire Inc.
Sanofi and IGM Biosciences Announce Collaboration Agreement for Oncology, Immunology and Inflammation Targets
Communiqué de presse: Sanofi poursuit sa trajectoire de leadership en immunologie avec Dupixent® (dupilumab) comme levier de croissance
01:00am, Tuesday, 29'th Mar 2022 GlobeNewswire Inc.
Sanofi poursuit sa trajectoire de leadership en immunologie avec Dupixent® (dupilumab) comme levier de croissance
Press Release: Sanofi continues on path to industry leadership in Immunology with Dupixent® (dupilumab) as key driver
01:00am, Tuesday, 29'th Mar 2022 GlobeNewswire Inc.
Sanofi continues on path to industry leadership in Immunology with Dupixent® (dupilumab) as key driver
Press Release: Xenpozyme® (olipudase alfa) approved in Japan, first and only approved therapy indicated to treat acid sphingomyelinase deficiency
07:00am, Monday, 28'th Mar 2022 GlobeNewswire Inc.
Communiqué de presse : Approbation de Xenpozyme® (olipudase alpha) au Japon – premier et seul médicament approuvé pour le traitement du déficit en sphingomyélinase acide
07:00am, Monday, 28'th Mar 2022 GlobeNewswire Inc.
Sanofi: Informations relatives au nombre de droits de vote et d'actions – FEVRIER 2022
04:45pm, Saturday, 26'th Mar 2022 GlobeNewswire Inc.
Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marc
Sanofi: Information concerning the total number of voting rights and shares – February 2022
04:45pm, Saturday, 26'th Mar 2022 GlobeNewswire Inc.
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement
Press release: Late-breaking Phase 3 data at AAD 2022 show Dupixent® (dupilumab) significantly improved signs and symptoms of prurigo nodularis
02:00pm, Saturday, 26'th Mar 2022 GlobeNewswire Inc.
Late-breaking Phase 3 data at AAD 2022 show Dupixent® (dupilumab) significantly improved signs and symptoms of prurigo nodularis
Communiqué de presse: Des données de phase III de dernière minute présentées au Congrès 2022 de l’AAD montrent que Dupixent® (dupilumab) améliore significativement les signes et symptômes du prurigo nodulaire
02:00pm, Saturday, 26'th Mar 2022 GlobeNewswire Inc.
Des données de phase III de dernière minute présentées au Congrès 2022 de l’AAD montrent que Dupixent® (dupilumab) améliore significativement les signes et symptômes du prurigo nodulaire
